Also known as R-1439, Ro-0728804
Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes. It is no longer in phase III clinical trials.
~1 min read
{{chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 477246742 | ImageFile = Aleglitazar.svg | ImageClass = skin-invert-image | ImageSize = 200px | PIN = (2S)-2-Methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid | OtherNames = Ro-0728804, R-1439 |Section1= |Section2= |Section3= }}
Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes. It is no longer in phase III clinical trials.
via Wikidata sitelinks · CC0
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).